Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target.
GI cancers
Gas6
anti-AXL antibodies
small molecule inhibitors
targeted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
10
2022
accepted:
31
05
2023
medline:
20
7
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
epublish
Résumé
Gastrointestinal (GI) cancers that include all cancers of the digestive tract organs are generally associated with obesity, lack of exercising, smoking, poor diet, and heavy alcohol consumption. Treatment of GI cancers typically involves surgery followed by chemotherapy and/or radiation. Unfortunately, intrinsic or acquired resistance to these therapies underscore the need for more effective targeted therapies that have been proven in other malignancies. The aggressive features of GI cancers share distinct signaling pathways that are connected to each other by the overexpression and activation of AXL receptor tyrosine kinase. Several preclinical and clinical studies involving anti-AXL antibodies and small molecule AXL kinase inhibitors to test their efficacy in solid tumors, including GI cancers, have been recently carried out. Therefore, AXL may be a promising therapeutic target for overcoming the shortcomings of standard therapies in GI cancers.
Identifiants
pubmed: 37469409
doi: 10.3389/fonc.2023.1079041
pmc: PMC10353021
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1079041Informations de copyright
Copyright © 2023 Pidkovka and Belkhiri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Annu Rev Pathol. 2008;3:157-88
pubmed: 18039136
Mol Cell Biol. 1993 Aug;13(8):4976-85
pubmed: 8336730
Neoplasia. 2018 Oct;20(10):1008-1022
pubmed: 30189359
Oncogene. 2007 Jun 7;26(27):3909-19
pubmed: 17325667
World J Gastroenterol. 2012 Oct 14;18(38):5369-76
pubmed: 23082053
Cancers (Basel). 2020 Jul 09;12(7):
pubmed: 32660000
Br J Cancer. 2019 Mar;120(5):512-521
pubmed: 30765873
Cancers (Basel). 2016 Oct 21;8(10):
pubmed: 27775650
Clin Gastroenterol Hepatol. 2021 May;19(5):876-884
pubmed: 32147593
Clin Cancer Res. 2016 Mar 15;22(6):1313-7
pubmed: 26763248
Science. 2001 Jul 13;293(5528):306-11
pubmed: 11452127
Cancer Res. 2015 Sep 15;75(18):3699-705
pubmed: 26206560
Cell Immunol. 2018 Sep;331:49-58
pubmed: 29935762
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9
pubmed: 20080645
Elife. 2014 Sep 29;3:
pubmed: 25265470
Int J Cancer. 2015 Jul 15;137(2):385-394
pubmed: 25529751
Onco Targets Ther. 2020 Jun 22;13:5901-5911
pubmed: 32606800
Lung Cancer. 2021 May;155:127-135
pubmed: 33798902
Mol Cancer Ther. 2011 Oct;10(10):1763-73
pubmed: 21933973
Mol Cell Biol. 1999 Dec;19(12):8075-82
pubmed: 10567533
Acta Anat (Basel). 1995;154(1):8-20
pubmed: 8714286
Clin Sci (Lond). 2012 Apr;122(8):361-8
pubmed: 22187964
Front Oncol. 2021 May 27;11:650963
pubmed: 34123800
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385724
Cancer Res. 2007 May 1;67(9):4408-17
pubmed: 17483355
Curr Opin Genet Dev. 2008 Feb;18(1):73-9
pubmed: 18325754
Gynecol Oncol. 2021 Nov;163(2):254-261
pubmed: 34474927
Oncogene. 2009 Oct 1;28(39):3442-55
pubmed: 19633687
Oncotarget. 2017 Nov 11;8(62):105727-105734
pubmed: 29285287
Cancers (Basel). 2016 Nov 09;8(11):
pubmed: 27834845
Int J Mol Sci. 2021 Sep 15;22(18):
pubmed: 34576116
Br J Cancer. 2017 Feb 14;116(4):415-423
pubmed: 28072762
Oncotarget. 2016 Jan 26;7(4):4093-109
pubmed: 26675259
Cancer Res. 2005 Oct 15;65(20):9294-303
pubmed: 16230391
Mol Cancer Ther. 2013 Sep;12(9):1749-62
pubmed: 23804704
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Res. 2019 Nov 15;79(22):5758-5768
pubmed: 31585940
Cancer Res. 2010 Feb 15;70(4):1544-54
pubmed: 20145120
Cancer Res. 2021 Feb 1;81(3):698-712
pubmed: 33239426
Oncotarget. 2019 Apr 23;10(30):2887-2898
pubmed: 31080559
Cancer Biol Ther. 2010 Nov 15;10(10):1009-18
pubmed: 20818175
Sci Rep. 2016 Jul 13;6:29673
pubmed: 27406916
Oncotarget. 2017 Jun 13;8(31):50403-50414
pubmed: 28881571
Theranostics. 2018 Nov 12;8(21):5890-5902
pubmed: 30613269
Nat Immunol. 2006 Jul;7(7):747-54
pubmed: 16751775
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Med Oncol. 2021 Feb 11;38(3):24
pubmed: 33570712
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13373-8
pubmed: 25187556
J Biol Chem. 1996 Nov 22;271(47):30022-7
pubmed: 8939948
Nat Rev Cancer. 2014 Dec;14(12):769-85
pubmed: 25568918
Cancer Res. 2013 Jan 1;73(1):331-40
pubmed: 23117882
J Leukoc Biol. 2010 May;87(5):869-75
pubmed: 20103767
J Immunol. 2007 May 1;178(9):5635-42
pubmed: 17442946
Evid Based Complement Alternat Med. 2019 Jun 09;2019:2474805
pubmed: 31281396
Mol Cancer Res. 2017 Jun;15(6):753-764
pubmed: 28184013
Clin Immunol. 2016 Aug;169:58-68
pubmed: 27237127
Mol Cancer. 2019 May 14;18(1):94
pubmed: 31088471
Semin Cancer Biol. 2015 Dec;35 Suppl:S25-S54
pubmed: 25892662
Oncotarget. 2015 Sep 15;6(27):23281-96
pubmed: 25966280
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Cancer Res. 2017 Jul 15;77(14):3725-3732
pubmed: 28667075
J Hematol Oncol. 2020 Jan 16;13(1):6
pubmed: 31948451
J Exp Med. 2006 Aug 7;203(8):1891-901
pubmed: 16831897
Cancer. 2011 Feb 15;117(4):734-43
pubmed: 20922806
Mol Cell Biol. 1991 Oct;11(10):5016-31
pubmed: 1656220
EMBO J. 2006 Jan 11;25(1):80-7
pubmed: 16362042
Cancer Cell. 2015 Apr 13;27(4):533-46
pubmed: 25873175
Cancer Res. 2018 Jan 1;78(1):246-255
pubmed: 29180468
Mol Cancer Ther. 2016 Dec;15(12):2916-2925
pubmed: 27638856
Biomed Pharmacother. 2021 Jan;133:110909
pubmed: 33227701
Mol Carcinog. 2007 Feb;46(2):155-64
pubmed: 17186543
EBioMedicine. 2022 Jan;75:103797
pubmed: 34973624
Oncogene. 1997 Jun 5;14(22):2619-31
pubmed: 9178760
Oncogene. 2011 Mar 10;30(10):1229-40
pubmed: 21076472
Oncogene. 2019 Jul;38(27):5469-5485
pubmed: 30936462
Blood. 1994 Sep 15;84(6):1931-41
pubmed: 7521695
Nucleic Acids Res. 2011 Jan;39(Database issue):D1005-10
pubmed: 21097893
World J Gastroenterol. 2018 Sep 14;24(34):3834-3848
pubmed: 30228778
EMBO J. 2012 Apr 4;31(7):1692-703
pubmed: 22327215
J Oncol. 2010;2010:835680
pubmed: 20224655
Proc Natl Acad Sci U S A. 1988 Mar;85(6):1952-6
pubmed: 3279421
PLoS One. 2016 May 16;11(5):e0154767
pubmed: 27182739
Future Oncol. 2019 Feb;15(6):653-662
pubmed: 30648886
Cell. 2018 Aug 9;174(4):1034-1035
pubmed: 30096302
Curr Opin Immunol. 2003 Feb;15(1):31-6
pubmed: 12495730
Cell Mol Gastroenterol Hepatol. 2017 Mar 14;4(1):47-53
pubmed: 28560288
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
Hepatology. 2015 Mar;61(3):930-41
pubmed: 25251599
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Cancer Sci. 2019 Aug;110(8):2549-2557
pubmed: 31162771
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
Cold Spring Harb Perspect Biol. 2013 Jan 01;5(1):a008748
pubmed: 23284042
EMBO Rep. 2019 Aug;20(8):e47052
pubmed: 31353791
Acta Oncol. 2015 Jan;54(1):5-16
pubmed: 25430983
Mol Cancer Ther. 2020 Dec;19(12):2409-2421
pubmed: 33087511
Cell. 1995 Feb 24;80(4):661-70
pubmed: 7867073
Neoplasia. 2013 Mar;15(3):296-304
pubmed: 23479507
Mol Cancer Res. 2022 Feb;20(2):265-279
pubmed: 34670865
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13091-6
pubmed: 23878224
Oncogene. 1991 Nov;6(11):2113-20
pubmed: 1834974
J Thromb Haemost. 2010 Apr;8(4):838-44
pubmed: 20088931
Cancer Discov. 2016 Apr;6(4):382-99
pubmed: 26984351
Gastric Cancer. 2020 Sep;23(5):824-836
pubmed: 32239298
Nature. 1995 Feb 16;373(6515):623-6
pubmed: 7854420
J Biol Chem. 1997 Sep 12;272(37):23285-91
pubmed: 9287338
PLoS One. 2019 Aug 1;14(8):e0220101
pubmed: 31369645
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Pharmacol Ther. 2020 Jan;205:107419
pubmed: 31629009
Cancer Biol Ther. 2017 Sep 2;18(9):694-704
pubmed: 28886275
Novartis Found Symp. 2007;283:174-91; discussion 191-3, 238-41
pubmed: 18300422
Cancer Biol Ther. 2009 Apr;8(7):618-26
pubmed: 19252414
J Virol. 2018 Feb 12;92(5):
pubmed: 29237830
Mol Oncol. 2018 Dec;12(12):2191-2208
pubmed: 30353671
J Cancer. 2020 Aug 8;11(20):5867-5879
pubmed: 32922529
Oncotarget. 2016 Jun 14;7(24):36956-36970
pubmed: 27172793
Eur J Cancer. 2020 Oct;138:1-10
pubmed: 32818762
Front Oncol. 2019 Nov 06;9:1138
pubmed: 31781483
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Nat Med. 2021 Jan;27(1):34-44
pubmed: 33442008
Nat Rev Clin Oncol. 2011 Mar;8(3):151-60
pubmed: 21364688
Oncotarget. 2017 Jul 11;8(28):46234-46248
pubmed: 28526812
J Biol Chem. 1998 Mar 20;273(12):7123-6
pubmed: 9507025
Curr Med Sci. 2019 Dec;39(6):874-882
pubmed: 31845217
Gene. 1993 Dec 8;134(2):289-93
pubmed: 8262388
Liver Int. 2015 Mar;35(3):1010-23
pubmed: 24621440
Clin Cancer Res. 2014 Jan 1;20(1):164-75
pubmed: 24170546
Cancer Res. 2019 May 15;79(10):2669-2683
pubmed: 30877108
J Immunol. 2008 Feb 15;180(4):2522-30
pubmed: 18250462
Environ Toxicol Pharmacol. 2016 Jul;45:222-6
pubmed: 27327525